CoChat

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes

Open access
DeFronzo, Ralph A., Tripathy, Devjit · 2009 · Diabetes Care

The DOI matches its Crossref record; 110 of the 115 references it cites were found in a registry or an index; 22 of the 65 sources its claims cite were checked for support.

Abstract

Insulin resistance is a characteristic feature of type 2 diabetes and plays a major role in the pathogenesis of the disease (1,2). Although �-cell failure is the sine qua non for development of type 2 diabetes, skeletal muscle insulin resistance is considered to be the initiating or primary defect that is evident decades before �-cell failure and overt hyperglycemia develops (3,4). Insulin resistance is defined as a reduced response of target tissues (compared with subjects with normal glucose tolerance [NGT] without a family history of diabetes), such as the skeletal muscle, liver, and adipocytes, to

Overview

CoChat Summary

TL;DR

This review argues that skeletal muscle insulin resistance—especially impaired glycogen synthesis—is the initiating/primary defect in most type 2 diabetes, preceding β-cell failure and overt hyperglycemia. It concludes that overt diabetes requires β-cell failure to supervene, while muscle insulin resistance is already evident in normal glucose-tolerant high-risk relatives and prospective populations.

Key findings

  • Skeletal muscle is the predominant site of insulin-mediated postprandial glucose uptake: under euglycemic hyperinsulinemia, ∼80% of glucose uptake occurs in skeletal muscle; leg muscle glucose uptake plateaus at ∼10 mg/kg leg weight per minute after 60 min, and in lean type 2 diabetic subjects it is reduced by ∼50% during the last hour of the insulin clamp.
  • In lean NGT offspring of two type 2 diabetic parents, a two-step euglycemic clamp (20 and 40 mU/m² per min; plasma insulin ∼40 and ∼80 μU/ml) showed glucose uptake decreased by 33% and 43%, respectively; the impairment was accounted for entirely by reduced nonoxidative glucose metabolism/glycogen synthesis, with no defect in insulin suppression of hepatic glucose production.
  • Prospective Pima Indian data showed both progressors and nonprogressors had a further 11–14% reduction in insulin sensitivity; nonprogressors increased insulin secretion by 30%, whereas progression to type 2 diabetes was associated with a 78% decline in the acute insulin response to intravenous glucose.
  • Hyperinsulinemia itself worsens muscle insulin resistance: a 72 pmol/l (11 μU/ml) increase in plasma insulin for 72–96 h reduced insulin-stimulated glucose disposal by 30–40%, entirely via impaired nonoxidative glucose disposal; in rats, 7-day hyperinsulinemia reduced total-body glucose uptake, storage, and glycolysis by 39%, 62%, and 26%. Mitochondrial ATP production increased by 90% in NGT subjects without family history but only 5% in insulin-resistant offspring.

Methods

  • Narrative review/symposium article; no primary study design or new sample. It synthesizes human studies using the euglycemic insulin clamp (described as the gold standard), indirect calorimetry, muscle biopsy, femoral/forearm catheterization, PET, NMR spectroscopy, OGTT, and prospective follow-up.
  • Populations discussed include lean NGT first-degree relatives/offspring of two type 2 diabetic parents, Mexican Americans, Pima Indians, Caucasians in San Antonio, and type 2 diabetic subjects. Main analysis is qualitative synthesis of cited evidence.

Limitations

  • Stated: by the time hyperglycemia is manifest, multiple abnormalities (elevated glucose, FFA, and cytokines) coexist, making it extremely difficult to separate each defect’s contribution; at initial presentation it is not possible to define which defect came first.
  • Stated: it is unclear whether mitochondrial dysfunction leads to increased intramyocellular lipid and insulin resistance or increased muscle lipid leads to mitochondrial dysfunction and insulin resistance (“which is the cart and which is the horse”).
  • Evident: as a narrative review, it lacks systematic search, formal quality assessment, or meta-analysis; conclusions depend on selected cited studies, and several figures are in an online appendix rather than the text.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2337/dc09-s302

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

14 Valid · 1 Not valid · 22 Not checked · 11 Own results and interpretations

21 more claims · 6 with their cited sources checked

Create a free account to see all 48 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 4
  • It may state two separate claims as one. 20

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 110 references

Research works printed but not linked: 2

  1. Pendergrass, 2007, Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals, Am J Physiol Endocrinol Metab, 292, E92, 10.1152/ajpendo.00617.2005 · DOI · Paper page
  2. Morino, 2005, Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents, J Clin Invest, 115, 3587, 10.1172/jci25151 · DOI · Paper page

Cited by

Items 501–600 of 2,099

Metadata

Authors
DeFronzo, R. A., & Tripathy, D.
Affiliations
The University of Texas at San Antonio Health Science Center (US)
Corresponding author
Tripathy, Devjit
Venue
Diabetes Care
Published
2009-11-01
Volume
32
Issue
suppl_2
Pages
S157-S163
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2170869159
Cited by
2,102
References
115
Citations by year
2026: 149 · 2025: 188 · 2024: 187 · 2023: 161 · 2022: 200 · 2021: 199 · 2020: 161 · 2019: 146 · 2018: 166 · 2017: 132 · 2016: 119 · 2015: 99 · 2014: 72 · 2013: 54 · 2012: 29
FWCI
2.87
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
skeletal muscle insulin resistance, type 2 diabetes, insulin resistance, beta-cell failure, type 2 diabetes pathogenesis, glucose tolerance, hyperglycemia
MeSH terms
Insulin Secretion, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Acids, Nonesterified, Homeostasis, Humans, Insulin, Insulin Resistance, Glucose Clamp Technique, Muscle, Skeletal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.